BLOG

Artificial Intelligence is no longer just a buzzword for the future—it is already embedded in our manufacturing plants, quality systems, and lab environments. Yet, when it comes to regulatory scrutiny, a significant gap remains. The gap between rapid AI adoption and finalized regulatory guidance is exactly where compliance risk lives. Here is the reality: regulators are not waiting for finalized guidance to ask hard questions. Inspectors are already asking, “How do you know t

Building on our recent breakdown of FDA cGMP standards for 503B outsourcing facilities, we are now looking at where these compliance expectations are tested the most: the inspection process. Join us as we explore recent FDA inspection trends and how to sustainably reinforce your quality management systems. While 503A compounding pharmacies prepare customized medications on a patient-specific basis under state board oversight, 503B outsourcing facilities operate on a larger sc

As an Industrial Pharmacist and long-time consultant in the manufacturing bio-pharmaceutical space, I’ve been following the growing trend of compounding pharmacies in the USA. It is now more common to find Warning Letters issued to compounding pharmacies, due to more scrutiny from the FDA. Let’s try to understand what the difference and what prompts a pharmacy to fall into a difficult compliance situation that may jeopardize not only the safety of its patients, but the expos